ClinicalTrials.gg
CompletedNCT03015909Updated Jan 3, 2019

Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.

A Phase 4 interventional study of Somatropin in Short Stature, Idiopathic, Infant, Small for Gestational Age and Growth Hormone Deficiency, sponsored by LG Life Sciences. Completed at 1 site in Korea, Republic of. Open to participants aged 4 Years to 15 Years. Per ClinicalTrials.gov, last updated 2019-01-03.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
4 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing Human Growth Hormone in Dwarfism — none open to participants now, 1 under way, none of them phase 3. Human Growth Hormone · Dwarfism.

Enrollment
6th of 15
116 · median 68
Started
2016
the only one that year
Phase 4
4 of 15
none open now
Registered
11th of 15
by date
Lead sponsor
1 of 15
LG Life Sciences

Among the 15 studies testing Human Growth Hormone in Dwarfism, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 4 in phase 4, and was the 11th registered.

Dwarfism

99 studies on the registry are indexed under Dwarfism; 12 are open to participants now.

Browse Dwarfism studies →

Open to participants now

None of the 15 studies testing Human Growth Hormone in Dwarfism is open now. The open studies under Dwarfism, anywhere →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Dwarfism studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 4 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing Human Growth Hormone in Dwarfism as a file.
02

Study summary

The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.

03

Conditions studied

  • Short Stature, Idiopathic
  • Infant, Small for Gestational Age
  • Growth Hormone Deficiency
  • Chronic Renal Failure
  • Turner Syndrome
04

Who can participate

Ages eligible
4 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who has been using reusable device growth hormone injection in recent 3 months at least for 6 weeks
  • Subjects who meets the indication of EutropinPen inj.

Exclusion criteria

Exclusion Criteria:

  • Subjects who has diseases below on screening visit

    • Diabetes
    • Malignant tumor
    • Epiphyseal closure
    • Chronic kidney disease (recieved kidney transplantation)
    • Acute respitory failure
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Other
    Eutropin pen inj.

    Drug: Somatropin

Interventions

06

What researchers measure

Primary outcomes

  1. Ease of use for EutropinPen Inj. against previous reusable device assessed by a questionnaire.

    Time frame: Day 57

  2. Preference for EutropinPen Inj. against previous reusable device assessed by a questionnaire.

    Time frame: Day 57

Secondary outcomes

  1. Benefits of EutropinPen inj. assessed by a questionnaire

    1. Ease of use 2. Unit 3. High dose packing 4. Grip 5. Design 6. Less pain

    Time frame: Day 57

  2. Fear assessed by a questionnaire

    Ask of fearness how the child feels about the needle

    Time frame: Screening, Day 57

  3. Ease of use for EutropinPen Inj. at each injection step assessed by a questionnaire

    1. Ask ease of use at each injection step (1\~5 pts) 2. Preparation time for injection

    Time frame: Screening, Day 57

  4. Treatment compliance of EutropinPen Inj. (%)

    Time frame: Day 57

07

Study locations

1 site
  • Ajou university hospital
    Suwon, Gyeong-gi 16499, Korea, Republic of
08

References and documents

Publications

  • Lee JE, Kim SY, Yoo JH, Hwang IT, Lim JS, Yi KH, Rhie YJ, Lee GM, Nam HK, Chae HW, Kim EY, Cheon CK, Lee J, Shim YS, Lee Y, Kim EY, Hwang JS. Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial. Patient Prefer Adherence. 2019 Dec 20;13:2195-2205. doi: 10.2147/PPA.S229536. eCollection 2019. PubMed 31908426 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Dec 2017, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2016
First posted
Jan 10, 2017
StartActual
Aug 11, 2016
Primary completionActual
Dec 21, 2017
CompletionActual
Dec 21, 2017
Last update
Jan 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03015909
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Jan 10, 2017
Start date
Aug 11, 2016
Primary completion
Dec 21, 2017
Completion
Dec 21, 2017
Last update
Jan 3, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion